A novel transcriptional pathway of chronic inflammation in metabolic syndrome
Project/Area Number |
23890116
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Metabolomics
|
Research Institution | Okayama University |
Principal Investigator |
EGUCHI Jun 岡山大学, 岡山大学病院, 助教 (60616366)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | メタボリック症候群 / 慢性炎症 / メタボリックシンドローム / IRF4 / マクロファージ / インスリン抵抗性 |
Research Abstract |
The enormous burden of metabolic disease in our society requires that we seek novel therapeutic strategies. Chronic inflammation inmetabolic syndrome leads to reduced systemic insulin sensitivity. In this study, we found that IRF4 is a negative regulator of inflammation in metabolic syndrome. IRF4 might be a novel therapeutic target for insulin resistance.
|
Report
(3 results)
Research Products
(13 results)
-
-
[Journal Article] RXR antagonism induces G(0)/G(1) cell cycle arrest and ameliorates obesity by up-regulating the p53-p21 pathway in adipocytes.2012
Author(s)
Nakatsuka A, Wada J, Hida K, Hida A,Eguchi J, Teshigawara S, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Ogawa D, Kagechika H, Makino H
-
Journal Title
J Pathol
Volume: 226
Pages: 784-95
Related Report
Peer Reviewed
-
[Journal Article] Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at serpina12 genetically defines distinct group with higher serum levels in japanese population.2012
Author(s)
Teshigawara S, Wada J, Hida K, Nakatsuka A, Eguchi J,Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Iseda I, Matsushita Y, Miyatake N, McDonald JF, Hotta K, Makino H
-
Journal Title
J Clin Endocrinol Metab
Volume: 97(7)
Pages: 1202-7
NAID
Related Report
Peer Reviewed
-
[Journal Article] Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes.2011
Author(s)
Kanzaki M, Wada J, Sugiyama K, Nakatsuka A, Teshigawara S, Murakami K, Inoue K, Terami T, Katayama A, Eguchi J,Makino H
-
Journal Title
Endocrinology
Volume: 153(2)
Pages: 612-20
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-